27 C
Vientiane
Thursday, June 19, 2025
spot_img
Home Blog Page 55

Timor-Leste to Become ASEAN’s 11th Member, Says Malaysian PM

Timor-Leste will be accepted as the 11th full member of the Association of Southeast Asian Nations (ASEAN), Malaysian Prime Minister Anwar Ibrahim announced. (Photo: tirto)

Timor-Leste will be accepted as the 11th full member of the Association of Southeast Asian Nations (ASEAN), Malaysian Prime Minister Anwar Ibrahim announced.

According to Malaysia’s national news agency, Anwar said ASEAN leaders had reached a consensus to support Timor-Leste in completing the necessary steps for full membership in the regional bloc.

The decision, he stated, is for Timor-Leste to be officially admitted by the ASEAN Summit in October, pending the completion of one or two key reforms, particularly in the economic sphere. Anwar made the announcement during a press conference at the conclusion of the 46th ASEAN Summit on 27 May.

Timor-Leste first applied for ASEAN membership in 2011 and was granted observer status in 2022, allowing participation in high-level meetings. Full membership, however, has been under deliberation at the leadership level in recent summits.

Timor-Leste’s Prime Minister, Xanana Gusmão, attended the May Summit in Malaysia.

During the summit, Malaysian PM Anwar noted that ASEAN leaders have tasked ministers and senior officials with finalizing procedural steps for Timor-Leste’s admission by the upcoming 47th ASEAN Summit in October. They have also been directed to expedite negotiations on key economic agreements.

The statement indicated that they had tasked the ASEAN Coordinating Council, with the support of all relevant ASEAN Sectoral Ministerial Bodies and the ASEAN Secretariat, to extend the necessary support to facilitate Timor-Leste’s integration into the ASEAN community.

CirCode Biomed Announces FDA Clearance for IND Application of HM2002, the world’s first circular RNA drug being administrated in patients

SHANGHAI, May 31, 2025 /PRNewswire/ — Shanghai CirCode Biomed Co. Ltd. (CirCode), an innovative biotech company pioneering circular RNA therapies, recently announced that its leading pipeline HM2002 received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for ischemic heart disease on May 30, 2025.

With the first patient administrated on September of 2024 in an investigator initiated trial (IIT), HM2002 is the world’s first circular RNA drug ever being used in patients. It received IND approval from the National Medical Products Administration (NMPA) of China on January 10th, 2025. HM2002 is currently the first circular RNA therapy to receive IND clearance in both China and the United States, and is also the only circular RNA drug globally approved for clinical study on patients with ischemic heart disease.

With the global aging population, ischemic heart disease shows a steadily rising incidence, and has been the leading cause of death globally for the past decades. The current standard of care shows limited effects in promoting myocardial microcirculation reconstruction and angiogenesis, leading to suboptimal efficacy and limited benefit in 10-year survival. There is an urgent unmet medical need for next generation therapies to improve patients’ prognosis and quality of life.

With the advantages of improved stability and low immunogenicity from circular RNAs, HM2002 can safely and continuously express vascular endothelial growth factor (VGEF) in the myocardium, which promotes angiogenesis, improves myocardial perfusion, and facilitates cardiac function recovery. It has demonstrated excellent safety and efficacy in the preclinical studies. In the first-in-human IIT at Ruijin Hospital initiated last year, all subjects showed significant cardiac function improvement without any drug-related adverse events.

“To promote angiogenesis and relief ischemia through VEGF overexpression is a well-tested solution, but there is a tremendous challenge to achieve an efficient, persistent, and controllable expression of VEGF in vivo. We find an excellent match between the need and the properties of circular RNA. A single dose of HM2002 can express VEGF protein for a perfect time window in vivo: long enough for efficient angiogenesis, short enough for any safety concerns. Once the microcirculation reformed, it brings long-lasting benefits to patients without the presence of HM2002 or VEGF protein,” said Dr. Chenxiang Tang, CEO of CirCode. “The IND clearances from both NMPA and FDA for HM2002 is a strong recognition for our innovation and competitiveness in the circular RNA therapeutic industry.

Dr. Yun Yang, co-founder, chairman, and chief technology officer of CirCode, stated that, “CirCode’s robust, proprietary circular RNA platform laid the foundation for the fast IND approval of HM2002. With the help of our AI tools, we were able to leap from a concept to IND approval of HM2002 in less than 2 years. We now have built a strong pipeline portfolio in various fields such as therapeutic proteins, vaccines, and in vivo CAR-T, covering multiple therapeutic areas such as cardiovascular diseases, infectious diseases, autoimmune diseases, and oncology. These pipelines have showed a favorable risk benefit profile with great efficacy and safety data in preclinical settings, many of which will enter the clinical stage within the next year. We are so excited to keep pushing the frontier of circular RNA therapy forward and providing more innovative therapies for patients.”

About CirCode

CirCode is a clinical-stage biotechnology company specializing in circular RNA therapeutics. Leveraging strong science and deep know-how, the company has built a fully integrated and proprietary platform, protected by a comprehensive global patent network, paving the way for the development of circular RNA therapeutics. Focusing on unmet medical needs, CirCode has built a robust pipeline targeting vaccines, cardiovascular diseases, autoimmune disorders, and oncology. CirCode is backed by top-tier investors and has received strong recognitions from leading pharmaceutical companies. Circode is committed to promoting the transformation of scientific and technological achievements and realizing the benefit of science and technology for mankind.

More information please visit www.circodebio.com

Or contact info@circodebio.com for business cooperation.

Illuminating ctDNA-MRD: Gene Solutions’ K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology

DA NANG, Vietnam, May 31, 2025 /PRNewswire/ — May 9-11, 2025, Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. — This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA)Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP).

Under the theme “Empowering the Potential of ctDNA-MRD,” 16 distinguished speakers and panelists shared clinical insights, breakthrough research, and innovative strategies for integrating ctDNA-MRD into cancer practice.

“While ctDNA and MRD are invisible to the eye, K-CONNECT APAC 2025 shed transformative light on their potential through regional collaboration and clinical innovation,” said Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions. “Illuminating ctDNA-MRD means revealing actionable insights that spark hope, clarity, and progress through molecular insights to transform precision oncology.”

“K-CONNECT APAC 2025 was a transformative moment for precision oncology in the Asia-Pacific, bringing together diverse expertise to translate ctDNA-MRD advancements into real-world clinical impact” said Professor Nick Pavlakis, Co-Chair of the summit and a leading medical oncologist from Australia. “This summit has set a new benchmark for collaborative innovation, paving the way for personalized cancer care across the region”

A First-of-Its-Kind Gathering in Asia-Pacific

Gene Solutions, a regional pioneer in ctDNA-MRD testing, has supported over 6,000 cancer patients via its next generation comprehensive AI-powered K-TRACK® and K-4CARE® platforms. K-CONNECT APAC 2025 showcased its role in fostering cross-border expertise to accelerate adoption of precision diagnostics.

The summit featured three key sessions shared by 16 esteemed experts

K-CONNECT ACADEMIC Session :

  • The Importance of ctDNA-MRD and CGP in Precision Oncology
  • Unique Combination of Genomic & Transcriptomic Profiling with ctDNA-MRD Monitoring
  • Key findings from Asia’s First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors.

K-CONNECT CASE SHARING Session

  • ctDNA-MRD Applications & Real-World Case Sharing in Colorectal, Lung and Breast cancers.

K-CONNECT NEXT  LANDMARK Session

  • Genetic Testing Guided Personalized Immunotherapy in Refractory Solid Tumors.
  • Triad of Impact– A Multi-omic Solution to Advance Precision Oncology Innovation.

Beyond an Event — Establishing a Platform for Ongoing Impact

K-CONNECT is evolving into a regional hub for knowledge exchange, clinical collaborations, and precision oncology innovation acceleration. Upcoming initiatives include:

  • K-CONNECT Webinar Series – Ongoing expert-led case discussions
  • Clinical Trials Collaboration – Cross-border partnerships with biopharma and research institutions
  • Experience ctDNA-MRD Program – Hands-on implementation support for clinicians
  • Knowledge Hub – A digital platform for APAC oncology insights

Shaping the Future of Cancer Care

K-CONNECT APAC 2025 solidified Gene Solutions’ leadership in genetic testing and its commitment to advancing equitable access to innovative solutions to improve patient outcomes. By fostering collaboration and showcasing real-world impact, the summit laid the foundation for a more connected, data-driven, and patient-centered future in cancer care across the Asia-Pacific.

About Gene Solutions

Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring.

With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific.

Explore more information at: https://genesolutions.com/ 

MEDIA CONTACT: pr@genesolutions.com

Arctech to Supply 175 MW of Solar Trackers for Landmark Green Hydrogen Project in Oman

DUQM, Oman, May 31, 2025 /PRNewswire/ — Arctech, the global leader in solar tracking, racking, and BIPV solutions, has signed a strategic contract with ACME Cleantech Solutions Pvt. Ltd. a pure play fully integrated Renewable Energy Company in India with a diversified portfolio across solar, wind, hybrid and FDRE projects to supply 175 MWp of solar trackers for the 300 MTPD Green Ammonia Project in Duqm, Oman.

The project is located near the southeastern coast of Oman, a region characterized by coastal desert conditions including sandy soils, high wind speeds (up to 55 m/s), C5-level corrosion exposure, extreme temperatures and high levels of solar radiation, with an annual average of around 5,764 KWh/m2. The area’s favourable climate, with high solar insolation, has made it a prime location for utility-scale solar projects.

Arctech will deploy its Signature 1P Single Axis Solar Tracking System Skyline II, engineered for harsh environments, to support the solar PV component powering one of the first large-scale green hydrogen production facilities in the region. The trackers will be delivered in phases starting from July 2025.

In recent years, Oman Power and Water Procurement Company (OPWP) has introduced renewable energy initiatives such as a new Concentrated Solar Power (CSP) project in Duqm. OPWP is actively working toward a diverse energy mix, aligning with the national target of sourcing 35–39% of electricity from renewables by 2040. This new partnership reinforces Oman’s long-term vision and positions the Duqm region as a central hub in the global energy transition.

This milestone collaboration underscores Arctech’s growing role in enabling renewable energy megaprojects worldwide. The Oman installation is a flagship initiative in industrial decarbonization—integrating solar power with next-gen hydrogen fuel technologies, setting new benchmarks in clean energy integration. Moreover, Arctech has an extensive track record of experience in numerous GW-scale large projects across the globe, which instils confidence in this partnership.

“We are pleased to partner with Arctech for our 300 MTPD Green Hydrogen project in Duqm, Oman. This collaboration marks an important milestone in our green hydrogen journey, and we are confident that Arctech’s advanced tracking solutions and project execution capabilities will support us in achieving optimal energy efficiency and reliability under challenging coastal and high-wind site conditions,” said by Vipin Aggarwal, VP of Procurement in Green Hydrogen and International Business.

Celebrate Memorial Day with Extended Savings on Monport CO2 Laser Engraving Machines

NEW YORK, May 31, 2025 /PRNewswire/ — This Memorial Day, the ultimate opportunity to upgrade your laser engraving setup has been extended — bringing unbeatable deals on industry-leading CO2 and fiber laser machines. Monport Laser, a leading innovator in laser engraving and cutting technology, is extending its highly anticipated Memorial Day Sale to give customers more time to unlock deep savings and exclusive pre-sale benefits. From home studios to industrial floors, Monport’s cutting-edge CO2 laser machines lineup—including the powerful Monport Mega 70W, the sleek new Reno Series, and professional-grade fiber laser engravers—now comes with unbeatable Memorial Day savings.

The Memorial Day Sale Extension is now live on Monport Laser website and features tiered discounts across all CO2 laser engravers — making it easier than ever to power up productivity and precision.

Explore the full Memorial Day sale here.

Buy More, Save More — Memorial Day Savings Extended

Back by overwhelming demand, Monport’s “Buy More, Save More” campaign rewards customers at every investment level with tiered savings:

These exclusive savings apply to all Monport CO2 laser engraving machines, including both the Monport Mega 70W and the pre-sale Reno Series models. Whether you’re upgrading to a high-capacity desktop engraver like the Mega or getting in early on the next generation of Reno machines, now is the time to act.

Monport Mega 70W — Intelligent Desktop Engraving, Elevated

Designed for serious creators who demand high speed, accuracy, and versatility, the Monport Mega 70W CO2 Laser is the most advanced intelligent desktop engraver Monport has ever produced. Built to outperform others in its class, the Mega brings industrial power to a compact, user-friendly format ideal for home workshops and business studios alike.

The Monport Mega 70W allows creators to engrave everything from wood, leather, and acrylic to custom gifts and signage—without sacrificing speed or accuracy. Its powerful CO2 laser system, combined with smart automation, makes it a top-tier solution for growing businesses and experienced makers alike.

Limited-Time Pricing:

This pricing is available only during the extended Memorial Day sale. Once the event ends, the Mega returns to its original retail price.

Get Started with Monport Mega Savings!

Pre-Order the Reno Series — Get a Free Gift Valued Up to $300

In addition to the Monport Mega, Monport is launching the all-new Reno Series, including the Reno 45W, Reno 45W Pro, and Reno 65W models. These CO2 laser engravers are built for creators who demand speed, efficiency, and cutting-edge design.

To celebrate the Reno Series pre-sale, Monport is offering an exclusive pre-order promotion:

Choose One Free Gift with Your Reno Pre-Order:

These gifts are only available during the limited-time pre-sale period. All Reno orders will ship within 60 days, and once this offer ends—there are no second chances.

With customers already praising the Monport Mega for its reliability and performance, the Reno Series is poised to deliver the same engineering excellence with a new, streamlined design.

Pre-Order Your Laser Today!

More Power. More Savings. More Possibilities.

From the versatile Monport Mega 70W to the future-forward Reno Series, Monport is leading the CO2 laser engraving industry with machines that balance power, speed, and usability. Backed by responsive U.S.-based support, detailed training resources, and continuous product innovation, Monport empowers creators at every level—from side-hustlers to production professionals.

This extended Memorial Day promotion provides a rare opportunity to secure the best equipment Monport has to offer at a fraction of the cost.

A Deal for Every Maker

From schools and sign shops to Etsy entrepreneurs and hardware labs, Monport’s extended Memorial Day deals are strategically crafted to provide solutions for every budget and workflow. The company continues to lead in customer-first innovation, offering best-in-class support, easy-to-use machines, and scalable engraving solutions for wood, acrylic, leather, glass, and more.

As the maker movement continues to grow, Monport Laser empowers individuals and teams to cut, engrave, and innovate with confidence.

Availability & Deadlines

The extended Memorial Day Sale is available now through Monport’s official website. Shoppers are encouraged to act quickly as inventory is limited, and gift availability for Reno Series pre-orders is first come, first served.

Don’t Miss This Opportunity:

About Monport

Monport is dedicated to revolutionizing the laser engraving industry by offering state-of-the-art solutions that combine power, precision, and ease of use. With a commitment to innovation, quality, and customer satisfaction, Monport provides a diverse range of CO2 and fiber laser machines designed for businesses, makers, and industrial professionals. Backed by expert support and continuous advancements, Monport helps users unlock new creative possibilities and elevate their engraving capabilities.

CASEKOO and LittleManyu Unveil “Pawfect Chill Time” – A Whimsical, Heart-Healing Collection Offering a Cozy Escape from Busy Lives

LOS ANGELES, May 31, 2025 /PRNewswire/ — Premium tech accessory brand CASEKOO proudly unveils its latest collaboration: “Pawfect Chill Time” — a heartwarming, cozy collection crafted in partnership with the beloved and widely adored dog Manyu (@littlemanyu_). With over 30 million followers across social media, Manyu has captured hearts across the nation with her irresistibly cute moments and comforting, slice-of-life charm.

Drawing inspiration from her signature chill time, the collection embodies the essence of mindful rest and emotional healing — designed to bring comfort, calm, and a dose of chillness to everyday life. At the heart of the collection is the Magic Stand case, featuring Manyu’s playful, fluffy face adorably curled up in her lounging style, ready for a bubble bath or a soothing massage.

But the magic doesn’t stop there. Hidden behind the stand is a delightful surprise — swappable MagStickers showcasing different versions of Manyu in her most comforting moments. From bath-time bliss to cozy nap scenes, each sticker captures her unique chill mode and can be effortlessly swapped in and out, letting you personalize your case and carry a touch of cuteness wherever you go.

It all serves as a gentle reminder: even amid the chaos of work, study, and daily stress, we all deserve a moment to slow down, breathe, and simply be.

“We created this collection to encourage people to slow down and breathe,” said Ralph, CASEKOO’s founder. “Whether it’s a short nap, a warm bubble bath, or just a few quiet minutes to yourself, these little moments of chill time can truly heal.”

A Cozy Companion: What’s Beyond a Healing Moment with Pawfect Chill Time

The Magic Stand technology is as functional as it is charming. It seamlessly combines a kickstand, a finger ring holder for a secure grip, and a MagSafe-compatible magnetic circle — all in one sleek design. The latest Pro version takes versatility to the next level with full 360° rotation, giving users the freedom to position their phone at virtually any angle with ease and comfort.

Paired with Manyu’s irresistibly cozy face, “Pawfect Chill Time” isn’t just a phone case collection — it’s a joyful expression of personality, warmth, and mindful self-care. Whether you’re looking for a personalized dog phone case, a custom pet case, or simply love cute animal designs, this limited-edition collaboration blends heart and function seamlessly into your everyday tech. Packaged in exclusive boxes adorned with Manyu’s signature style, each case celebrates the sweet simplicity of rest in a fast-paced world.

Manyu’s art resonates deeply with the idea that healing can be simple and sweet — a message CASEKOO is proud to bring into people’s lives through this beautiful collaboration.

To discover more, visit https://casekoo.com/manyu-global-portal.

REALTY ONE GROUP EXPANDS INTO THE DOMINICAN REPUBLIC

Visionary Franchise Partner Brings the Fast-Growing Real Estate Brand to Its 27th Country

LAGUNA NIGUEL, Calif., May 31, 2025 /PRNewswire/ — Realty ONE Group International, a modern, purpose-driven lifestyle brand and ONE of the fastest-growing real estate franchisors in the world, has announced the sale of ownership rights for the Dominican Republic, marking its entry into the dynamic Caribbean market and its 27th country worldwide.

Sergio Gonzalez, who currently holds the master franchise rights for Costa Rica, Panama, Belize, Jamaica and the Grand Cayman Islands and has driven impressive growth and momentum in the region, is now expanding his vision as the new owner of the Dominican Republic.

“We’re excited to partner again with Sergio whose shared vision for our ONE Family has already made a meaningful difference in Costa Rica and beyond,” said Kuba Jewgieniew, CEO and Founder of Realty ONE Group International. “His pure passion for the business and his mastering of the Latin American market will fuel phenomenal growth in the Dominican Republic.”

With over 30 years of powerhouse experience in business, management, and real estate, Sergio Gonzalez brings unstoppable passion to Realty ONE Group Dominican Republic.
“The Dominican Republic is not just important — it’s a game-changing gateway in our global expansion,” said Sergio Gonzalez. “This market is bursting with opportunity, and we’re here to elevate real estate professionals with cutting-edge tools, bold COOLTURE, and world-class support to help them dominate and thrive.”

Realty ONE Group was recently named the No. 1 real estate brand for the fourth year in a row on Entrepreneur’s prestigious 2025 Franchise 500® list. The brand now includes more than 450 offices and over 20,000 real estate professionals across 49 U.S. states and 27 countries and territories.

Learn more at www.OwnAOne.com or www.join.realtyonegroup.com.

About Realty ONE Group International
Realty ONE Group International is one of the fastest growing, modern, purpose-driven lifestyle brands in real estate whose ONE Purpose is to open doors across the globe – ONE home, ONE dream, ONE life at a time. The organization has rapidly grown to more than 20,000 real estate professionals in over 450 locations across 27 countries and territories because of its proven business model, full-service brokerages, dynamic COOLTURE, superior business coaching through ONE University, outstanding support and its proprietary technology, zONE. Realty ONE Group International has been named the number ONE real estate brand by Entrepreneur Magazine for three consecutive years and continues to surge ahead, opening doors, not only for its clients but for real estate professionals and franchise owners. To learn more, visit www.RealtyONEGroup.com.

 

9F Inc. Announces Receipt of Nasdaq Notification Regarding Late Filing of Form 20-F

BEIJING, May 31, 2025 /PRNewswire/ — 9F Inc. (“9F” or the “Company”) (Nasdaq: JFU), a digital technology service provider aiming to empower institutional partners with advanced financial technologies, today announced that it received a notification letter dated May 23, 2025 (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”), indicating that the Company is not in compliance with the requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) since the Company did not timely file its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “2024 Form 20-F”) with the Securities and Exchange Commission (the “SEC”).

The Notification Letter has no immediate effect on the listing of the Company’s American depositary shares on Nasdaq. Pursuant to the Nasdaq Listing Rules, the Company has 60 calendar days from the date of the Notification Letter to submit a plan to regain compliance with Nasdaq Listing Rules (the “Compliance Plan”). If Nasdaq accepts the Compliance Plan, it may grant the Company an extension until November 11, 2025 to regain compliance. The Company expects either to file its 2024 Form 20-F or submit the Compliance Plan within the prescribed 60-day period.

The Company was not able to file the 2024 Form 20-F by the prescribed deadline as extended pursuant to Rule 12b-25(b)(2)(ii) under the Securities Exchange Act of 1934, primarily because the Company is unable to complete the audit of the financial statements of the Company for the fiscal year ended December 31, 2024 and the preparation for the 2024 Form 20-F. The Company continues to work diligently to complete the 2024 Form 20-F and intends to file it with the SEC as soon as reasonably practicable. This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Such statements are based upon management’s current expectations and current market, regulatory and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company’s ability to continue or to complete its ongoing business transformation, its ability to attract and retain investors on its platform, its ability to apply for or obtain any license, its ability to expand into any new market, its ability to compete effectively, its ability to comply with any applicable laws, regulations and governmental policies in China or elsewhere, general economic conditions in China and elsewhere, and the Company’s ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq, including its ability to cure any non-compliance with the Nasdaq’s continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. Neither track record nor past performance is indicative of future results. 9F Inc. does not guarantee any specific outcome (including the outcome of its ongoing business transformation) or profit.

All information provided in this press release is as of the date of this press release, and subject to change without notice. 9F Inc. does not undertake any obligation to update information contained herein as a result of new information, future events or otherwise, except as required under applicable law.

For investor and media enquiries, please contact:

In China:
9F Inc.
E-mail: ir@9fgroup.com